【摘要】 IgA肾病(IgA nephropathy，IgAN)是全球最常见的原发性肾小球疾病，其病理机制的核心是循环中含有IgA的免疫复合物与系膜细胞结合，继发肾小球炎症和小管间质纤维化。长期以来IgAN的临床疗法多侧重于对症支持治疗及全身应用糖皮质激素，但仍有相当大比例的患者进展为终末期肾脏病(end-stage renal disease，ESRD)。随着对IgAN发病机制的深入了解，新的治疗靶点及药物正在被开发，包括内皮素系统阻断、肠道黏膜免疫系统和B细胞靶向治疗及补体抑制等。本综述概述了目前、最近批准和新兴的IgAN治疗方法。更多还原

【Abstract】 IgA Nephropathy (IgAN) is the most common primary glomerular disease worldwide,and its pathological mechanism revolves around the binding of circulating immune complexes containing IgA to mesangial cells,leading to secondary glomerular inflammation and tubulointerstitial fibrosis.For a long time,clinical therapy for IgAN has mainly focused on symptomatic supportive treatment and systemic application of glucocorticoids,but a considerable proportion of patients still progress to end-stage renal disease (ESRD).With a deeper understanding of the pathogenesis of IgAN,new therapeutic targets and drugs are being developed,including blockade of the endothelin system,targeted therapy of the intestinal mucosal immune system and B cells,and complement inhibition.This review provides an overview of current,recently approved,and emerging IgAN treatment methods.更多还原